

**Request for Prior Authorization
OMALIZUMAB (XOLAIR)**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

| | | |
|--|-----------------|---------|
| IA Medicaid Member ID # | Patient name | DOB |
| Patient address | | |
| Provider NPI | Prescriber name | Phone |
| Prescriber address | | Fax |
| Pharmacy name | Address | Phone |
| Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. | | |
| Pharmacy NPI | Pharmacy fax | NDC |

Prior authorization (PA) is required for omalizumab (Xolair) prefilled syringe. Requests for omalizumab (Xolair) lyophilized powder for reconstitution will not be considered through the pharmacy benefit. Request must adhere to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations. Payment for omalizumab (Xolair) prefilled syringe will be considered under the following conditions:

1. Therapy will be initiated in a healthcare setting, under the guidance of a healthcare provider, where the patient can be closely observed for anaphylaxis and safety of therapy has been established after a minimum of 3 doses of omalizumab; and
2. The healthcare provider has determined self-administration with omalizumab is appropriate based on careful assessment of risk for anaphylaxis and mitigation strategies, as outlined in the label; and
3. Prescriber is an allergist, dermatologist, immunologist, otolaryngologist or pulmonologist; and
4. For a diagnosis of asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and any other FDA approved diagnosis where dosing is dependent on serum IgE level and body weight, the pretreatment IgE level and body weight, in kilograms (kg), is provided. Note: according to the label, there is insufficient data to recommend a dose for certain pretreatment serum IgE levels and body weight. PA requests will be denied in these instances; and
5. Patient has access to an epinephrine injection to treat allergic reactions that may occur after administration of omalizumab (Xolair); and
6. Prescriber and dispensing pharmacy will educate patient on proper storage and administration. Improperly stored medications will not be replaced.

Moderate to Severe Persistent Asthma:

1. Patient has a diagnosis of moderate to severe persistent asthma for at least one year, and
2. Patient has a history of positive skin or RAST test to a perennial aeroallergen; and
3. Patient is currently using a high dose inhaled corticosteroid, long-acting beta-agonist, AND leukotriene receptor antagonist, and is compliant with therapy and asthma symptoms are not adequately controlled after at least three (3) months of therapy.

If the criteria for coverage are met, the initial authorization will be given for 16 weeks to assess the need for continued therapy. Requests for continuation of therapy will not be granted for patients who have not shown adequate response to omalizumab (Xolair) therapy and for patients who do not continue concurrent use with a high dose inhaled corticosteroid, long-acting beta-agonist, and leukotriene receptor antagonist.

Chronic Idiopathic Urticaria:

1. Patient has a diagnosis of moderate to severe chronic urticaria; and
2. Patient has documentation of a trial and therapy failure with at least one preferred second- generation antihistamine, one of which must be cetirizine at a dose up to 20mg per day; and
3. Patient has documentation of a trial and therapy failure with at least one preferred first-generation antihistamine; and
4. Patient has documentation of a trial and therapy failure with at least one preferred potent H1 receptor antagonist (hydroxyzine and/or doxepin); and
5. Patient has documentation of a trial and therapy failure with a preferred leukotriene receptor antagonist in combination with a first- or second- generation antihistamine.

**Request for Prior Authorization
OMALIZUMAB (XOLAIR)**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

If criteria for coverage are met, the initial authorization will be given for 12 weeks to assess the need for continued therapy. Requests for continuation of therapy will not be granted for patients who have not shown adequate response to omalizumab (Xolair) therapy.

Nasal Polyps:

1. Patient has a diagnosis of nasal polyps; and
2. Patient has documentation of an adequate trial and inadequate response with at least two nasal corticosteroids at a maximally tolerated dose; and
3. Will be used concurrently with a nasal corticosteroid.

If criteria for coverage are met, the initial authorization will be given for 24 weeks to assess the need for continued therapy. Requests for continuation of therapy will not be granted for patients who have not shown adequate response to omalizumab (Xolair) therapy and for patients who do not continue concurrent use with a nasal corticosteroid.

IgE Mediated Food Allergy:

1. Medication is being prescribed for the reduction of allergic reactions (Type 1) that may occur with accidental exposure to one or more foods in a patient that has an IgE-mediated food allergy; and
2. Diagnosis is confirmed by a skin prick test or in vitro test (attach results); and
3. Will be used in conjunction with food allergen avoidance.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred Xolair prefilled syringe

| Strength | Dosage Instructions | Quantity | Days Supply |
|----------|---------------------|----------|-------------|
| _____ | _____ | _____ | _____ |

Diagnosis: _____

Was therapy initiated in a healthcare setting, under the guidance of a healthcare provider for a minimum of 3 doses? Yes Date dose 1: _____ Date dose 2: _____ Date dose 3: _____ No

Has healthcare provider determined self-administration is appropriate based on careful assessment of risk for anaphylaxis and mitigation strategies, as outlined in the label? Yes No

Prescriber Specialty: Allergist Dermatologist Immunologist Otolaryngologist Pulmonologist

Other (specify): _____

Patient has access to epinephrine injection: Yes No

Has patient been educated on proper storage and administration? Yes No

Pretreatment IgE level: _____ Date Obtained: _____

Patient's Weight (kg): _____ Date Obtained: _____

Moderate to Severe Persistent Asthma:

Date of diagnosis: _____

Inhaled Corticosteroid trial: Drug Name: _____ Strength: _____ Instructions: _____

Trial dates: _____

**Request for Prior Authorization
OMALIZUMAB (XOLAIR)**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Inhaled Long-Acting Beta-Agonist trial: Drug Name: _____ Strength: _____ Instructions: _____

Trial dates: _____

Leukotriene Receptor Antagonist trial: Drug Name: _____ Strength: _____ Instructions: _____

Trial dates: _____

Medical or contraindication reason to override trial requirements: _____

History of positive skin or RAST test to a perennial aeroallergen: Yes No Date Performed: _____**For Renewals Only: Has patient shown adequate response to Xolair[®] therapy?** Yes No

Please describe: _____

Moderate to Severe Chronic Idiopathic Urticaria:**Preferred Second-Generation Antihistamine trial:** Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Preferred First-Generation Antihistamine trial: Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Preferred Potent H1 receptor antagonist trial: Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Preferred Leukotriene Receptor Antagonist in combination with a preferred first-or second- generation antihistamine:**Preferred Leukotriene Receptor Antagonist trial:** Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Preferred First-or Second-Generation Antihistamine trial: Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

For Renewals Only: Has patient shown adequate response to Xolair[®] therapy? Yes No

Please describe: _____

Nasal Polyps:**Nasal Corticosteroid Trials:****Trial 1:** Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Trial 2: Drug Name: _____ Strength: _____

Dosing Instructions: _____ Trial dates: _____

Will omalizumab be used concurrently with a nasal corticosteroid? Yes Drug Name: _____ No

**Request for Prior Authorization
OMALIZUMAB (XOLAIR)**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

For Renewals Only: Has patient shown adequate response to Xolair[®] therapy? Yes No

Please describe: _____

Is patient currently using a nasal corticosteroid? Yes No

IgE Mediated Food Allergy:

Is medication being prescribed for the reduction of Type 1 allergic reactions that may occur with accidental exposure to one or more foods in a patient that has an IgE-mediated food allergy? Yes No

Is diagnosis confirmed by a skin prick test or in vitro test? Yes (attach results) No

Will requested medication be used in conjunction with food allergen avoidance? Yes No

Medical or contraindication reason to override trial requirements: _____

Attach lab results and other documentation as necessary.

| | |
|--|--------------------|
| Prescriber signature (Must match prescriber listed above.) | Date of submission |
|--|--------------------|

IMPORTANT NOTE: *In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.*